CheekAge: next-generation buccal epigenetic aging clock
GeroScience publication: Tally Health's CheekAge predicts all-cause mortality via cheek-swab DNA methylation.
OVUM Editorial·
Executive summary
GeroScience publication: Tally Health's CheekAge predicts all-cause mortality via cheek-swab DNA methylation. Companion paper extended the validation to mortality prediction in blood-based datasets — establishing buccal-swab epigenetic testing as a non-invasive biomarker of biological age. OVUM files this under prevention and biomarkers in women's health.
Key findings
- Companion paper extended the validation to mortality prediction in blood-based datasets — establishing buccal-swab epigenetic testing as a non-invasive biomarker of biological age.
Market implications
- Most aging biomarkers were validated in mixed or male populations, so women-specific reference ranges are still being established.
- A preventive product needs sex-specific evidence before an employer or payer will fund it.
- Measurement alone is widely available. What distinguishes a product is the intervention it triggers.
Interpretative layer
Professional access includes investor relevance, OVUM view, and category-level implications.
Source and methodology
Compiled from the published article, its classification, and OVUM's internal taxonomy. Last indexed Jun 12, 2026.
Article summary
Companion paper extended the validation to mortality prediction in blood-based datasets — establishing buccal-swab epigenetic testing as a non-invasive biomarker of biological age.